Animal studies show experimental injection reverses osteoarthritis

Researchers at the University of Colorado Boulder have demonstrated that a single injected drug-delivery system can reverse osteoarthritis in animals within weeks. The team, led by chemical and biological engineer Stephanie Bryant, reported success in early animal experiments. They aim to advance to human trials after further safety testing.

A team from the University of Colorado Boulder has developed an experimental slow-release drug-delivery system that, when injected into damaged joints, prompts the body's cartilage and bone cells to repair osteoarthritis effectively in just weeks, according to ongoing animal experiments not yet peer-reviewed. Stephanie Bryant stated, 'In two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals.' The researchers are now preparing for phase two, which will assess safety and toxicology to pave the way for human clinical trials within the next 18 months, pending results from additional animal studies. Bryant's goal is clear: 'not just to treat pain and halt progression, but to end this disease.' Currently, osteoarthritis—a condition affecting hundreds of millions worldwide with no cure—leaves patients managing pain or undergoing joint replacements. Evalina Burger, professor and chair of the Department of Orthopedics at UC Anschutz, noted, 'At the moment, the options for many patients are either a massive, expensive surgery or nothing. There's not a lot in between.' The team is also working on an injectable implant to recruit cells for cartilage repair, offering options for different stages of the disease. Funding comes from the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program under ARPA-H, part of the US Department of Health and Human Services. ARPA-H Director Alicia Jackson said, 'Through ARPA-H, we are driving toward a future where people don't have to wake up in pain, give up activities they love, or face major surgeries and repeat joint replacements – so they can stay active, independent, and healthy for longer.'

Awọn iroyin ti o ni ibatan

Split-image illustration depicting knee cartilage regeneration in mice and human tissue from a Stanford Medicine study on 15-PGDH inhibitor.
Àwòrán tí AI ṣe

Stanford study finds 15-PGDH inhibitor regrew knee cartilage in mice and slowed osteoarthritis changes in human tissue

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Stanford Medicine researchers report that blocking the enzyme 15-PGDH reversed age-related cartilage loss in older mice and reduced osteoarthritis-like damage after ACL-like knee injuries. In lab experiments, cartilage taken from knee replacement surgeries also showed early signs of regeneration after exposure to the inhibitor, findings published in *Science*.

Millions worldwide suffer from osteoarthritis, yet many miss out on the most effective treatment: exercise. Experts highlight that movement nourishes joints and reduces pain more than surgery or medications in many cases. Studies show fewer than half of diagnosed patients receive referrals for physical activity programs.

Ti AI ṣe iroyin

Researchers at University College London have discovered how the body naturally shuts down inflammation using fat-derived molecules called epoxy-oxylipins. These molecules prevent the buildup of immune cells linked to chronic diseases like arthritis and heart disease. A study involving a drug that boosts these molecules showed faster pain relief and reduced harmful immune activity.

Researchers at Stanford Medicine have created an experimental nasal spray vaccine that protects mice against multiple respiratory threats, including COVID-19, flu, bacterial pneumonia, and allergens. The vaccine activates the lungs' innate immune system for months, offering broad defense without targeting specific pathogens. Published in Science on February 19, the study suggests potential for human trials soon.

Ti AI ṣe iroyin

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ